Immix Biopharma, Inc. Income Statement
IMMX|3 years of annual SEC 10-K data (FY2023-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Immix Biopharma, Inc. reported $20M in revenue and $22M in net loss for FY2025. Revenue has grown at a 0.0% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $20.0M | $20.0M | $20.0M |
| SG&A Expense | $11.4M | $7.4M | $4.0M |
| R&D Expense | $11.3M | $8.7M | $4.2M |
| Operating Income | -$22.7M | -$16.1M | -$8.2M |
| Interest Expense | - | - | $497 |
| Income Tax | $41.0K | $26.4K | $10.3K |
| Net Income | -$21.6M | -$15.4M | -$8.2M |
| EPS (Basic) | -$0.76 | -$0.89 | -$0.59 |
| EPS (Diluted) | -$0.76 | -$0.89 | -$0.59 |
| Shares Outstanding | 27.5M | 19.9M | 13.9M |
| Operating Margin | -113.4% | -80.7% | -41.1% |
| Profit Margin | -108.1% | -77.1% | -41.1% |